Advertisement
Screener

Viking Therapeutics, Inc. (VKTX) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Viking Therapeutics, Inc. Stock-Based Compensation

Viking Therapeutics, Inc. (VKTX) reported Stock-Based Compensation of $11.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-07-29

  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $11.13M, a 17.82% decline year-over-year.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $10.34M, a 8.91% decline year-over-year.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $8.59M, a 51.53% increase year-over-year.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.34M, a 18.33% decline year-over-year.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $40.82M, a 37.38% increase from fiscal 2024.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $29.71M, a 77.39% increase from fiscal 2023.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $16.75M, a 93.13% increase from fiscal 2022.
  • Viking Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $8.67M, a 42.18% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 3 month as first filedShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 6 month as first filedShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 9 month as first filedShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 12 month as first filed
2026-06-30$11.13M
10-Q · filed 2026-07-29
$21.47M
10-Q · filed 2026-07-29
$30.06M
derived: sum of 3 quarters · filed 2026-07-29
$37.39M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$10.34M
10-Q · filed 2026-04-30
$18.92M
derived: sum of 2 quarters · filed 2026-04-30
$26.26M
derived: sum of 3 quarters · filed 2026-04-30
$39.81M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$8.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11
$15.92M
derived: sum of 2 quarters · filed 2026-02-11
$29.47M
derived: sum of 3 quarters · filed 2026-07-29
$40.82M
10-K · filed 2026-02-11
2025-09-30$7.34M
10-Q · filed 2025-10-23
$20.88M
derived: sum of 2 quarters · filed 2026-07-29
$32.23M
10-Q · filed 2025-10-23
$37.90M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$13.55M
10-Q · filed 2026-07-29
$24.89M
10-Q · filed 2026-07-29
$30.56M
derived: sum of 3 quarters · filed 2026-07-29
$39.54M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$11.35M
10-Q · filed 2026-04-30
$17.02M
derived: sum of 2 quarters · filed 2026-04-30
$26.00M
derived: sum of 3 quarters · filed 2026-04-30
$33.08M
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31$5.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11
$14.65M
derived: sum of 2 quarters · filed 2026-02-11
$21.73M
derived: sum of 3 quarters · filed 2026-02-11
$29.71M
10-K · filed 2026-02-11
2024-09-30$8.98M
10-Q · filed 2025-10-23
$16.06M
derived: sum of 2 quarters · filed 2025-10-23
$24.05M
10-Q · filed 2025-10-23
$28.13M
derived: sum of 4 quarters · filed 2026-02-11
2024-06-30$7.08M
10-Q · filed 2025-07-23
$15.06M
10-Q · filed 2025-07-23
$19.14M
derived: sum of 3 quarters · filed 2026-02-11
$23.62M
derived: sum of 4 quarters · filed 2026-02-11
2024-03-31$7.98M
10-Q · filed 2025-04-24
$12.06M
derived: sum of 2 quarters · filed 2026-02-11
$16.54M
derived: sum of 3 quarters · filed 2026-02-11
$21.16M
derived: sum of 4 quarters · filed 2026-02-11
2023-12-31$4.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11
$8.56M
derived: sum of 2 quarters · filed 2026-02-11
$13.18M
derived: sum of 3 quarters · filed 2026-02-11
$16.75M
10-K · filed 2026-02-11
2023-09-30$4.48M
10-Q · filed 2024-10-23
$9.10M
derived: sum of 2 quarters · filed 2024-10-23
$12.67M
10-Q · filed 2024-10-23
$14.83M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$4.62M
10-Q · filed 2024-07-24
$8.19M
10-Q · filed 2024-07-24
$10.35M
derived: sum of 3 quarters · filed 2025-02-26
$12.29M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$3.57M
10-Q · filed 2024-04-25
$5.72M
derived: sum of 2 quarters · filed 2025-02-26
$7.67M
derived: sum of 3 quarters · filed 2025-02-26
$9.88M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$2.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$4.10M
derived: sum of 2 quarters · filed 2025-02-26
$6.32M
derived: sum of 3 quarters · filed 2025-02-26
$8.67M
10-K · filed 2025-02-26
2022-09-30$1.94M
10-Q · filed 2023-10-25
$4.16M
derived: sum of 2 quarters · filed 2023-10-25
$6.52M
10-Q · filed 2023-10-25
$7.95M
derived: sum of 4 quarters · filed 2024-02-07
2022-06-30$2.22M
10-Q · filed 2023-07-26
$4.58M
10-Q · filed 2023-07-26
$6.01M
derived: sum of 3 quarters · filed 2024-02-07
$7.61M
derived: sum of 4 quarters · filed 2024-02-07
2022-03-31$2.36M
10-Q · filed 2023-04-26
$3.79M
derived: sum of 2 quarters · filed 2024-02-07
$5.39M
derived: sum of 3 quarters · filed 2024-02-07
$6.88M
derived: sum of 4 quarters · filed 2024-02-07
2021-12-31$1.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07
$3.03M
derived: sum of 2 quarters · filed 2024-02-07
$4.52M
derived: sum of 3 quarters · filed 2024-02-07
$6.10M
10-K · filed 2024-02-07
2021-09-30$1.60M
10-Q · filed 2022-10-26
$3.09M
derived: sum of 2 quarters · filed 2022-10-26
$4.67M
10-Q · filed 2022-10-26
$5.71M
derived: sum of 4 quarters · filed 2022-10-26
2021-06-30$1.49M
10-Q · filed 2022-07-27
$3.07M
10-Q · filed 2022-07-27
$4.11M
derived: sum of 3 quarters · filed 2022-07-27
$5.58M
derived: sum of 4 quarters · filed 2022-07-27
2021-03-31$1.58M
10-Q · filed 2022-04-27
$2.62M
derived: sum of 2 quarters · filed 2022-04-27
$4.09M
derived: sum of 3 quarters · filed 2022-04-27
$5.74M
derived: sum of 4 quarters · filed 2022-04-27
2020-12-31$1.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09
$2.52M
derived: sum of 2 quarters · filed 2022-02-09
$4.16M
derived: sum of 3 quarters · filed 2022-02-09
$5.82M
10-K · filed 2022-02-09
2020-09-30$1.47M
10-Q · filed 2021-11-03
$3.12M
derived: sum of 2 quarters · filed 2021-11-03
$4.78M
10-Q · filed 2021-11-03
$5.75M
derived: sum of 4 quarters · filed 2021-11-03
2020-06-30$1.65M
10-Q · filed 2021-07-28
$3.30M
10-Q · filed 2021-07-28
$4.28M
derived: sum of 3 quarters · filed 2021-07-28
$5.09M
derived: sum of 4 quarters · filed 2021-07-28
2020-03-31$1.65M
10-Q · filed 2021-04-28
$2.63M
derived: sum of 2 quarters · filed 2021-04-28
$3.44M
derived: sum of 3 quarters · filed 2021-04-28
$4.36M
derived: sum of 4 quarters · filed 2021-04-28
2019-12-31$976.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17
$1.79M
derived: sum of 2 quarters · filed 2021-02-17
$2.71M
derived: sum of 3 quarters · filed 2021-02-17
$3.74M
10-K · filed 2021-02-17
2019-09-30$811.00K
10-Q · filed 2020-10-28
$1.73M
derived: sum of 2 quarters · filed 2020-10-28
$2.77M
10-Q · filed 2020-10-28
$3.38M
derived: sum of 4 quarters · filed 2020-10-28
2019-06-30$922.00K
10-Q · filed 2020-07-29
$1.96M
10-Q · filed 2020-07-29
$2.57M
derived: sum of 3 quarters · filed 2020-07-29
$3.32M
derived: sum of 4 quarters · filed 2020-07-29
2019-03-31$1.03M
10-Q · filed 2020-04-30
$1.65M
derived: sum of 2 quarters · filed 2020-04-30
$2.40M
derived: sum of 3 quarters · filed 2020-04-30
$3.03M
derived: sum of 4 quarters · filed 2020-04-30
2018-12-31$617.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
$1.37M
derived: sum of 2 quarters · filed 2020-02-26
$2.00M
derived: sum of 3 quarters · filed 2020-02-26
$2.61M
10-K · filed 2020-02-26
2018-09-30$750.00K
10-Q · filed 2019-11-05
$1.38M
derived: sum of 2 quarters · filed 2019-11-05
$1.99M
10-Q · filed 2019-11-05
$2.35M
derived: sum of 4 quarters · filed 2019-11-05
2018-06-30$630.00K
10-Q · filed 2019-08-01
$1.24M
10-Q · filed 2019-08-01
$1.60M
derived: sum of 3 quarters · filed 2019-08-01
$1.95M
derived: sum of 4 quarters · filed 2019-08-01
2018-03-31$610.00K
10-Q · filed 2019-05-02
$973.00K
derived: sum of 2 quarters · filed 2019-05-02
$1.32M
derived: sum of 3 quarters · filed 2019-05-02
$1.66M
derived: sum of 4 quarters · filed 2019-05-02
2017-12-31$363.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13
$707.00K
derived: sum of 2 quarters · filed 2019-03-13
$1.05M
derived: sum of 3 quarters · filed 2019-03-13
$1.45M
10-K · filed 2019-03-13
$1.45M
10-K · filed 2018-03-07
2017-09-30$344.00K
10-Q · filed 2018-11-07
$344.13K
10-Q · filed 2017-11-08
$685.00K
derived: sum of 2 quarters · filed 2018-11-07
$1.09M
10-Q · filed 2018-11-07
$1.09M
10-Q · filed 2017-11-08
$1.45M
derived: sum of 4 quarters · filed 2018-11-07
2017-06-30$341.00K
10-Q · filed 2018-08-09
$341.26K
10-Q · filed 2017-08-09
$743.00K
10-Q · filed 2018-08-09
$743.50K
10-Q · filed 2017-08-09
$1.10M
derived: sum of 3 quarters · filed 2018-08-09
$1.42M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$402.00K
10-Q · filed 2018-05-09
$402.24K
10-Q · filed 2017-05-10
$760.58K
derived: sum of 2 quarters · filed 2018-05-09
$1.08M
derived: sum of 3 quarters · filed 2018-05-09
$1.57M
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31$358.57K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07
$679.53K
derived: sum of 2 quarters · filed 2018-03-07
$1.17M
derived: sum of 3 quarters · filed 2018-03-07
$1.79M
10-K · filed 2018-03-07
2016-09-30$320.95K
10-Q · filed 2017-11-08
$811.20K
derived: sum of 2 quarters · filed 2017-11-08
$1.44M
10-Q · filed 2017-11-08
$1.96M
derived: sum of 4 quarters · filed 2017-11-08
2016-06-30$490.25K
10-Q · filed 2017-08-09
$1.11M
10-Q · filed 2017-08-09
$1.64M
derived: sum of 3 quarters · filed 2017-08-09
$2.24M
derived: sum of 4 quarters · filed 2017-08-09
2016-03-31$624.55K
10-Q · filed 2017-05-10
$1.15M
derived: sum of 2 quarters · filed 2017-05-10
$1.75M
derived: sum of 3 quarters · filed 2017-05-10
$3.23M
derived: sum of 4 quarters · filed 2017-05-10
2015-12-31$527.44K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21
$1.13M
derived: sum of 2 quarters · filed 2017-03-21
$2.60M
derived: sum of 3 quarters · filed 2017-03-21
$2.60M
10-K · filed 2017-03-21
2015-09-30$601.59K
10-Q · filed 2016-11-10
$0.00
10-Q · filed 2015-11-05
$2.07M
derived: sum of 2 quarters · filed 2016-11-10
$2.07M
10-Q · filed 2016-11-10
$2.07M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30$1.47M
10-Q · filed 2016-08-11
$1.47M
10-Q · filed 2016-08-11
$1.47M
derived: sum of 3 quarters · filed 2016-08-11
$1.48M
derived: sum of 4 quarters · filed 2016-08-11
2015-03-31$903.00
10-Q · filed 2016-05-10
$1.81K
derived: sum of 2 quarters · filed 2016-05-10
$5.21K
derived: sum of 3 quarters · filed 2016-05-10
$6.26K
derived: sum of 4 quarters · filed 2016-05-10
2014-12-31$903.00
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08
$4.30K
derived: sum of 2 quarters · filed 2016-03-08
$5.35K
derived: sum of 3 quarters · filed 2016-03-08
$6.26K
10-K · filed 2016-03-08
2014-09-30$3.40K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
$4.45K
derived: sum of 2 quarters · filed 2015-11-05
$5.36K
10-Q · filed 2015-11-05
2014-06-30$1.05K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14
$1.95K
10-Q · filed 2015-08-14
2014-03-31$904.00
10-Q · filed 2015-06-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Veradermics, Inc (MANE)United States$4.839B
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
Organon & Co. (OGN)United States$3.603B17.03
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Erasca, Inc. (ERAS)United States$5.073B-19.96